Pricing Log in Create free account

CRISPR Therapeutics AG (CRSP) vs Erasca, Inc. (ERAS)

CRISPR Therapeutics AG and Erasca, Inc. are both Biotechnology companies. CRISPR Therapeutics AG and Erasca, Inc. are of similar size ($4.7B and $4.6B). Erasca, Inc. has the higher net margin (0.00% vs −1,812.1%) and the lower return on invested capital (−203.1% vs 0.00%). Across the 14 metrics below, Erasca, Inc. leads on 8 and CRISPR Therapeutics AG on 6.

Valuation

Metric CRSP ERAS Biotechnology median
P/E n/m n/m 10.60
P/S 191.85 n/m 9.40
P/B 2.93 12.34 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 124.89 n/m 9.02
Earnings yield (9.50%) (6.62%) (32.88%)
Free cash flow yield (7.80%) (5.65%) (23.13%)

Profitability

Metric CRSP ERAS Biotechnology median
Gross margin 100.00% 0.00% 68.51%
Operating margin (2,114.75%) 0.00% 0.00%
Net margin (1,812.07%) 0.00% 0.00%
Free cash flow margin (1,496.56%) 0.00% 0.00%
Return on equity (25.60%) (78.25%) (51.96%)
Return on assets (19.00%) (65.25%) (46.06%)
Return on invested capital 0.00% (203.13%) 0.00%

Growth

Metric CRSP ERAS Biotechnology median
Revenue growth (TTM) (34.34%) — 6.76%
EPS growth (last fiscal year) (49.08%) 36.23% 29.88%
Revenue growth, 5-year CAGR 37.31% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CRSP ERAS Biotechnology median
Debt to equity 0.36 0.00 0.00
Current ratio 16.21 8.29 4.97
Net debt to EBITDA 3.06 1.93 1.01

Dividend

Metric CRSP ERAS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CRSP ERAS Biotechnology median
Market cap 4.71b 4.64b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack